Effect of the clopidogrel - Proton Pump Inhibitor drug interaction on adverse cardiovascular events in patients with Acute Coronary Syndrome

Sharvari M. Bhurke, Bradley C. Martin, Chenghui Li, Amy M. Franks, Zoran Bursac, Qayyim Said

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Study Objective. To examine the effect of the drug interaction between clopidogrel and proton pump inhibitors (PPIs) on the risk of an adverse cardiovascular event. Design. Population-based, retrospective cohort study. Data Source. IMS LifeLink Health Plan administrative claims database. Patients. A total of 10, 101 patients aged 18 years or older with a diagnosis of acute coronary syndrome (ACS) made during a hospitalization or emergency department visit between 2001 and 2008 and who had their first clopidogrel prescription within 90 days after their ACS diagnosis were included in the study. Patients were stratified according to concurrent use (clopidogrel plus PPI group) or no use (clopidogrel alone group) of the following PPIs: esomeprazole, lansoprazole, omeprazole, pantoprazole, or rabeprazole. Measurements and Main Results. Data were collected on baseline patient demographic and clinical characteristics. Patients were followed from their first clopidogrel prescription until they experienced an adverse cardiovascular event, defined as inpatient hospitalization or emergency department visits for myocardial infarction, percutaneous coronary intervention, or intermediate coronary syndrome; were disenrolled; discontinued clopidogrel; or reached the end of the study period. Using a propensity scoring method, the clopidogrel plus PPI group was matched in a 1:1 ratio with the clopidogrel alone group. Exposure to overlapping clopidogrel-PPI prescriptions was modeled as a time-dependent covariate. The Cox hazards regression model was used to estimate the risk of an adverse cardiovascular event in the clopidogrel plus PPI group versus the clopidogrel alone group. Propensity score matching resulted in 2674 patient pairs. In the propensity score-matched sample, the mean age was 61.30 years, with a mean follow-up of 268 days, and 70.04% were male. Concurrent use of clopidogrel with a PPI was associated with a significantly increased risk of a cardiovascular adverse event (hazard ratio 1.438, 95% confidence interval 1.237-1.671) compared with clopidogrel alone. Conclusion. Concurrent use of clopidogrel plus a PPI was associated with a significant increase in risk of an adverse cardiovascular event in patients with ACS. Large randomized studies are needed to confirm this finding. Until then, clinicians should prescribe the concurrent use of these two drugs cautiously.

Original languageEnglish (US)
Pages (from-to)809-818
Number of pages10
JournalPharmacotherapy
Volume32
Issue number9
DOIs
StatePublished - Sep 1 2012

Fingerprint

clopidogrel
Proton Pump Inhibitors
Acute Coronary Syndrome
Drug Interactions
Prescriptions
Propensity Score
Hospital Emergency Service
Hospitalization
Research Design

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Effect of the clopidogrel - Proton Pump Inhibitor drug interaction on adverse cardiovascular events in patients with Acute Coronary Syndrome. / Bhurke, Sharvari M.; Martin, Bradley C.; Li, Chenghui; Franks, Amy M.; Bursac, Zoran; Said, Qayyim.

In: Pharmacotherapy, Vol. 32, No. 9, 01.09.2012, p. 809-818.

Research output: Contribution to journalArticle

Bhurke, Sharvari M. ; Martin, Bradley C. ; Li, Chenghui ; Franks, Amy M. ; Bursac, Zoran ; Said, Qayyim. / Effect of the clopidogrel - Proton Pump Inhibitor drug interaction on adverse cardiovascular events in patients with Acute Coronary Syndrome. In: Pharmacotherapy. 2012 ; Vol. 32, No. 9. pp. 809-818.
@article{995bc0f2b9ad430abb442d6c935564d6,
title = "Effect of the clopidogrel - Proton Pump Inhibitor drug interaction on adverse cardiovascular events in patients with Acute Coronary Syndrome",
abstract = "Study Objective. To examine the effect of the drug interaction between clopidogrel and proton pump inhibitors (PPIs) on the risk of an adverse cardiovascular event. Design. Population-based, retrospective cohort study. Data Source. IMS LifeLink Health Plan administrative claims database. Patients. A total of 10, 101 patients aged 18 years or older with a diagnosis of acute coronary syndrome (ACS) made during a hospitalization or emergency department visit between 2001 and 2008 and who had their first clopidogrel prescription within 90 days after their ACS diagnosis were included in the study. Patients were stratified according to concurrent use (clopidogrel plus PPI group) or no use (clopidogrel alone group) of the following PPIs: esomeprazole, lansoprazole, omeprazole, pantoprazole, or rabeprazole. Measurements and Main Results. Data were collected on baseline patient demographic and clinical characteristics. Patients were followed from their first clopidogrel prescription until they experienced an adverse cardiovascular event, defined as inpatient hospitalization or emergency department visits for myocardial infarction, percutaneous coronary intervention, or intermediate coronary syndrome; were disenrolled; discontinued clopidogrel; or reached the end of the study period. Using a propensity scoring method, the clopidogrel plus PPI group was matched in a 1:1 ratio with the clopidogrel alone group. Exposure to overlapping clopidogrel-PPI prescriptions was modeled as a time-dependent covariate. The Cox hazards regression model was used to estimate the risk of an adverse cardiovascular event in the clopidogrel plus PPI group versus the clopidogrel alone group. Propensity score matching resulted in 2674 patient pairs. In the propensity score-matched sample, the mean age was 61.30 years, with a mean follow-up of 268 days, and 70.04{\%} were male. Concurrent use of clopidogrel with a PPI was associated with a significantly increased risk of a cardiovascular adverse event (hazard ratio 1.438, 95{\%} confidence interval 1.237-1.671) compared with clopidogrel alone. Conclusion. Concurrent use of clopidogrel plus a PPI was associated with a significant increase in risk of an adverse cardiovascular event in patients with ACS. Large randomized studies are needed to confirm this finding. Until then, clinicians should prescribe the concurrent use of these two drugs cautiously.",
author = "Bhurke, {Sharvari M.} and Martin, {Bradley C.} and Chenghui Li and Franks, {Amy M.} and Zoran Bursac and Qayyim Said",
year = "2012",
month = "9",
day = "1",
doi = "10.1002/j.1875-9114.2012.01112.x",
language = "English (US)",
volume = "32",
pages = "809--818",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Effect of the clopidogrel - Proton Pump Inhibitor drug interaction on adverse cardiovascular events in patients with Acute Coronary Syndrome

AU - Bhurke, Sharvari M.

AU - Martin, Bradley C.

AU - Li, Chenghui

AU - Franks, Amy M.

AU - Bursac, Zoran

AU - Said, Qayyim

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Study Objective. To examine the effect of the drug interaction between clopidogrel and proton pump inhibitors (PPIs) on the risk of an adverse cardiovascular event. Design. Population-based, retrospective cohort study. Data Source. IMS LifeLink Health Plan administrative claims database. Patients. A total of 10, 101 patients aged 18 years or older with a diagnosis of acute coronary syndrome (ACS) made during a hospitalization or emergency department visit between 2001 and 2008 and who had their first clopidogrel prescription within 90 days after their ACS diagnosis were included in the study. Patients were stratified according to concurrent use (clopidogrel plus PPI group) or no use (clopidogrel alone group) of the following PPIs: esomeprazole, lansoprazole, omeprazole, pantoprazole, or rabeprazole. Measurements and Main Results. Data were collected on baseline patient demographic and clinical characteristics. Patients were followed from their first clopidogrel prescription until they experienced an adverse cardiovascular event, defined as inpatient hospitalization or emergency department visits for myocardial infarction, percutaneous coronary intervention, or intermediate coronary syndrome; were disenrolled; discontinued clopidogrel; or reached the end of the study period. Using a propensity scoring method, the clopidogrel plus PPI group was matched in a 1:1 ratio with the clopidogrel alone group. Exposure to overlapping clopidogrel-PPI prescriptions was modeled as a time-dependent covariate. The Cox hazards regression model was used to estimate the risk of an adverse cardiovascular event in the clopidogrel plus PPI group versus the clopidogrel alone group. Propensity score matching resulted in 2674 patient pairs. In the propensity score-matched sample, the mean age was 61.30 years, with a mean follow-up of 268 days, and 70.04% were male. Concurrent use of clopidogrel with a PPI was associated with a significantly increased risk of a cardiovascular adverse event (hazard ratio 1.438, 95% confidence interval 1.237-1.671) compared with clopidogrel alone. Conclusion. Concurrent use of clopidogrel plus a PPI was associated with a significant increase in risk of an adverse cardiovascular event in patients with ACS. Large randomized studies are needed to confirm this finding. Until then, clinicians should prescribe the concurrent use of these two drugs cautiously.

AB - Study Objective. To examine the effect of the drug interaction between clopidogrel and proton pump inhibitors (PPIs) on the risk of an adverse cardiovascular event. Design. Population-based, retrospective cohort study. Data Source. IMS LifeLink Health Plan administrative claims database. Patients. A total of 10, 101 patients aged 18 years or older with a diagnosis of acute coronary syndrome (ACS) made during a hospitalization or emergency department visit between 2001 and 2008 and who had their first clopidogrel prescription within 90 days after their ACS diagnosis were included in the study. Patients were stratified according to concurrent use (clopidogrel plus PPI group) or no use (clopidogrel alone group) of the following PPIs: esomeprazole, lansoprazole, omeprazole, pantoprazole, or rabeprazole. Measurements and Main Results. Data were collected on baseline patient demographic and clinical characteristics. Patients were followed from their first clopidogrel prescription until they experienced an adverse cardiovascular event, defined as inpatient hospitalization or emergency department visits for myocardial infarction, percutaneous coronary intervention, or intermediate coronary syndrome; were disenrolled; discontinued clopidogrel; or reached the end of the study period. Using a propensity scoring method, the clopidogrel plus PPI group was matched in a 1:1 ratio with the clopidogrel alone group. Exposure to overlapping clopidogrel-PPI prescriptions was modeled as a time-dependent covariate. The Cox hazards regression model was used to estimate the risk of an adverse cardiovascular event in the clopidogrel plus PPI group versus the clopidogrel alone group. Propensity score matching resulted in 2674 patient pairs. In the propensity score-matched sample, the mean age was 61.30 years, with a mean follow-up of 268 days, and 70.04% were male. Concurrent use of clopidogrel with a PPI was associated with a significantly increased risk of a cardiovascular adverse event (hazard ratio 1.438, 95% confidence interval 1.237-1.671) compared with clopidogrel alone. Conclusion. Concurrent use of clopidogrel plus a PPI was associated with a significant increase in risk of an adverse cardiovascular event in patients with ACS. Large randomized studies are needed to confirm this finding. Until then, clinicians should prescribe the concurrent use of these two drugs cautiously.

UR - http://www.scopus.com/inward/record.url?scp=84867585759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867585759&partnerID=8YFLogxK

U2 - 10.1002/j.1875-9114.2012.01112.x

DO - 10.1002/j.1875-9114.2012.01112.x

M3 - Article

C2 - 22744772

AN - SCOPUS:84867585759

VL - 32

SP - 809

EP - 818

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 9

ER -